ReviewNature reviews. Nephrology2023
Diagnosis of cardiovascular disease in patients with chronic kidney disease.
Review in Nature reviews. Nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis.Clinical and experimental nephrology · 2024Pooled it
- Impact of resistance exercise on patients with chronic kidney disease.BMC nephrology · 2024Pooled it
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Letter to the Editor: Early identification of mortality risk in emergency patients with chronic kidney disease - insights from India with global implications.World journal of nephrology · 2026Article
- The Prevalence and Diagnostic of Silent Ischemic Heart Disease in Polish Kidney Transplant Candidates.Journal of clinical medicine · 2026Article
- Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD.Circulation research · 2026Review
- Fish oil supplements in patients with chronic kidney disease.Clinical kidney journal · 2026Review
- EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease.Exploration (Beijing, China) · 2026Article
- A narrative review of spatial multi-omics and organ-on-a-chip technologies for cardio-cerebral-renal crosstalk.Frontiers in bioengineering and biotechnology · 2026Review
- Clinical utility of the AITIS model for test-free identification of sarcopenia in patients with stage IV-V non-dialysis-dependent chronic kidney disease.Frontiers in nutrition · 2026Article
- Associations of chronic kidney disease with recurrent stroke in patients with intracerebral haemorrhage.European stroke journal · 2026Article
- Effects of the Brazilian Native Fruit Jaboticaba (Foods (Basel, Switzerland) · 2025Article
- The association between computed tomography-based intrapancreatic fat deposition and renal function.BMC nephrology · 2025Article
- Estradiol is not protective against angiotensin II-induced hypertension in middle-aged ovariectomized rats.Physiological reports · 2025Article
- ABCDE to identify and prevent chronic kidney disease: a call to action.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Nonatherosclerotic Cardiovascular Disease in Chronic Kidney Disease.Cardiology clinics · 2025Review
- The global burden of chronic kidney disease due to glomerulonephritis: trends and predictions.International urology and nephrology · 2025Article
- Patient-centred estimation of multimorbidity in chronic disease populations: a novel approach integrating global burden of disease metrics and healthcare administrative data.Population health metrics · 2025Article
- Review
- Clinical Utility of Atrioventricular Coupling Index in Cardiovascular Disease.Journal of the American Heart Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD) and cardiovascular death. Identifying and monitoring cardiovascular complications and hypertension is important for managing patients with CKD or kidney failure and transplant recipients. Biomarkers of myocardial ischaemia, such as troponins and electrocardiography (ECG), have limited utility for diagnosing cardiac ischaemia in patients with advanced CKD. Dobutamine stress echocardiography, myocardial perfusion scintigraphy and dipyridamole stress testing can be used to detect coronary disease in these patients. Left ventricular hypertrophy and left ventricular dysfunction can be detected and monitored using various techniques with differing complexity and cost, including ECG, echocardiography, nuclear magnetic resonance, CT and myocardial scintigraphy. Atrial fibrillation and other major arrhythmias are common in all stages of CKD, and ambulatory heart rhythm monitoring enables precise time profiling of these disorders. Screening for cerebrovascular disease is only indicated in asymptomatic patients with autosomal dominant polycystic kidney disease. Standardized blood pressure is recommended for hypertension diagnosis and treatment monitoring and can be complemented by ambulatory blood pressure monitoring. Judicious use of these diagnostic techniques may assist clinicians in detecting the whole range of cardiovascular alterations in patients with CKD and enable timely treatment of CVD in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.